This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Jul 2021

Salvat’s Pharmaloop Invests 65 million Euros in Its New Sterile Liquids Plant, located in Alcalá de Henares

The new 8,500 m² plant is equipped with the most advanced technology, highest quality standards and the capacity to produce more than 350 million units of sterile formulations per year.

The new Pharmaloop facility enhances production capabilities for the globe

The objective of the new facility is to produce for the world’s sterile liquids market, primarily North American. In addition to the previous need for single dose formats, the COVID-19 pandemic has increased demand dramatically, as this delivery system is a perfect fit for vaccines and other sterile pharmaceuticals.

“The manufacture of sterile single-dose liquids is a complex process that requires very advanced technology. Pharmaloop is a clear example of our commitment to advanced formulations in innovation, and thanks to this commitment, we will strength our presence internationally, especially in the United States” explains Alberto Bueno, CEO of Group Salvat.

The plant has the most advanced technology in medical production, such as the BFS (Blow, Fill and Seal) system. This formulation has exhaustive quality controls that ensure 100% of the vials are checked to avoid leaks.

Smart and sustainable facility

Pharmaloop is an 8,500 m², fully automated and sustainable small building that does not generate atmospheric emissions or noise.

It has a cogeneration system that transforms gas into electrical energy and allows it to operate completely autonomous. It also has a system that recovers the residual heat from the gases to produce hot water and steam.

The new facility has generated the creation of 100 qualified jobs, in addition to the 52 employees who already worked at the plant before its expansion. With this amplification, Salvat increases its production capacity and distinguishes itself as a leader in sterile liquid manufacturing with a truly international focus. The Group’s goal is to continue Salvat’s current growth trajectory with the aim of reaching 100 million euros in turnover. The company’s forecast is to grow by 30 people in the coming months and reach more than 70 countries in order to continue serving customers and patients worldwide.

Mentioned Companies
Laboratorios Salvat, S.A.
View company profile